Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603252472> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2603252472 abstract "160 Background: Circulating aberrations (copy number/point mutation] of androgen receptor ( AR) as well as serum chromogranin A (CgA) have been associated to treatment response and clinical outcome in CRPC patients (pts) treated with abiraterone (abi)/enzalutamide(enza). Methods: We determined AR aberrations by digital PCR, Taqman and targeted-next generation sequencing on pre-treatment plasma from 169 CRPC pts treated with abi 1g/od (n = 96) and prednisone 5mg/bid or enza 160mg/od (n = 73) (Romanel, 2015; Salvi, 2015; Salvi, 2016). All pts were subdivided into 3 groups using receiver-operating characteristic (ROC) curves (Burgio, 2014; Conteduca, 2014) to evaluate properly the impact of CgA levels: serum CgA level was normal when < 120 ng/ml (group A,n = 76); within 3 times the upper normal value(UNV) when between 120 and 360(group B,n = 57), more than 3 times UNV when > 360(group C,n = 36). The primary endpoint was the correlation between AR aberrations and CgA level. The secondary endpoints were progression-free/overall survival (PFS/OS) and PSA response rate (RR) ( > 50% PSA decline after 12 weeks of therapy) stratified by AR status and CgA level. Results: We observed AR gain in 57(33.7%) of 169 pts, 29(30.2%) of 96 pts treated with abi and 28(38.3%) of 73 treated with enza. Circulating AR status was independent from baseline CgA levels in all pts (p = 0.36). In only AR-normal pts, we showed a significant survival difference among 3 CgA groups (P < 0.0001), particularly Group C vs. A+B [HR (hazard ratio) 5.1, 95%CI (confidence interval) 2.37-10.96 and HR 3.7 95%CI 1.79-7.69, respectively for PFS/OS]. We reported no difference of PFS/OS in AR-gained pts (P = 0.6 and P = 0.1, respectively with HR~0.6 in all CgA groups). In addition, group C vs. A+B had a significant PSA RR [P = 0.03 odds ratio (OR) 2.7 95%CI 1.02-7.30] in AR-normal pts. No PSA RR difference was observed in AR-gained pts (P = 1.0 OR 0.97 95%CI 0.18-5.26). Conclusions: In CRPC pts treated with abi/enza, baseline CgA levels may be an additional predictive/prognostic factor, especially in a particular set of CRPC pts with normal plasma AR status and worse treatment outcome. This association needs a prospective larger study." @default.
- W2603252472 created "2017-04-07" @default.
- W2603252472 creator A5000156180 @default.
- W2603252472 creator A5002369059 @default.
- W2603252472 creator A5016213425 @default.
- W2603252472 creator A5030571299 @default.
- W2603252472 creator A5031994096 @default.
- W2603252472 creator A5042277842 @default.
- W2603252472 creator A5048745498 @default.
- W2603252472 creator A5056071446 @default.
- W2603252472 creator A5056449812 @default.
- W2603252472 creator A5071060598 @default.
- W2603252472 creator A5080883471 @default.
- W2603252472 creator A5089119498 @default.
- W2603252472 date "2017-02-20" @default.
- W2603252472 modified "2023-10-02" @default.
- W2603252472 title "Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide." @default.
- W2603252472 doi "https://doi.org/10.1200/jco.2017.35.6_suppl.160" @default.
- W2603252472 hasPublicationYear "2017" @default.
- W2603252472 type Work @default.
- W2603252472 sameAs 2603252472 @default.
- W2603252472 citedByCount "0" @default.
- W2603252472 crossrefType "journal-article" @default.
- W2603252472 hasAuthorship W2603252472A5000156180 @default.
- W2603252472 hasAuthorship W2603252472A5002369059 @default.
- W2603252472 hasAuthorship W2603252472A5016213425 @default.
- W2603252472 hasAuthorship W2603252472A5030571299 @default.
- W2603252472 hasAuthorship W2603252472A5031994096 @default.
- W2603252472 hasAuthorship W2603252472A5042277842 @default.
- W2603252472 hasAuthorship W2603252472A5048745498 @default.
- W2603252472 hasAuthorship W2603252472A5056071446 @default.
- W2603252472 hasAuthorship W2603252472A5056449812 @default.
- W2603252472 hasAuthorship W2603252472A5071060598 @default.
- W2603252472 hasAuthorship W2603252472A5080883471 @default.
- W2603252472 hasAuthorship W2603252472A5089119498 @default.
- W2603252472 hasConcept C121608353 @default.
- W2603252472 hasConcept C126322002 @default.
- W2603252472 hasConcept C126894567 @default.
- W2603252472 hasConcept C134018914 @default.
- W2603252472 hasConcept C143998085 @default.
- W2603252472 hasConcept C203092338 @default.
- W2603252472 hasConcept C204232928 @default.
- W2603252472 hasConcept C2776421732 @default.
- W2603252472 hasConcept C2776551883 @default.
- W2603252472 hasConcept C2778720950 @default.
- W2603252472 hasConcept C2780192828 @default.
- W2603252472 hasConcept C535046627 @default.
- W2603252472 hasConcept C61367390 @default.
- W2603252472 hasConcept C71924100 @default.
- W2603252472 hasConcept C77231918 @default.
- W2603252472 hasConceptScore W2603252472C121608353 @default.
- W2603252472 hasConceptScore W2603252472C126322002 @default.
- W2603252472 hasConceptScore W2603252472C126894567 @default.
- W2603252472 hasConceptScore W2603252472C134018914 @default.
- W2603252472 hasConceptScore W2603252472C143998085 @default.
- W2603252472 hasConceptScore W2603252472C203092338 @default.
- W2603252472 hasConceptScore W2603252472C204232928 @default.
- W2603252472 hasConceptScore W2603252472C2776421732 @default.
- W2603252472 hasConceptScore W2603252472C2776551883 @default.
- W2603252472 hasConceptScore W2603252472C2778720950 @default.
- W2603252472 hasConceptScore W2603252472C2780192828 @default.
- W2603252472 hasConceptScore W2603252472C535046627 @default.
- W2603252472 hasConceptScore W2603252472C61367390 @default.
- W2603252472 hasConceptScore W2603252472C71924100 @default.
- W2603252472 hasConceptScore W2603252472C77231918 @default.
- W2603252472 hasLocation W26032524721 @default.
- W2603252472 hasOpenAccess W2603252472 @default.
- W2603252472 hasPrimaryLocation W26032524721 @default.
- W2603252472 hasRelatedWork W1977298801 @default.
- W2603252472 hasRelatedWork W2001873673 @default.
- W2603252472 hasRelatedWork W2011216433 @default.
- W2603252472 hasRelatedWork W2077039324 @default.
- W2603252472 hasRelatedWork W2080914447 @default.
- W2603252472 hasRelatedWork W2084738681 @default.
- W2603252472 hasRelatedWork W2121953515 @default.
- W2603252472 hasRelatedWork W2165834169 @default.
- W2603252472 hasRelatedWork W2279750117 @default.
- W2603252472 hasRelatedWork W2289725873 @default.
- W2603252472 hasRelatedWork W2390467622 @default.
- W2603252472 hasRelatedWork W2416842215 @default.
- W2603252472 hasRelatedWork W2561171916 @default.
- W2603252472 hasRelatedWork W2599269456 @default.
- W2603252472 hasRelatedWork W2624208483 @default.
- W2603252472 hasRelatedWork W2736944995 @default.
- W2603252472 hasRelatedWork W2897371497 @default.
- W2603252472 hasRelatedWork W2982033774 @default.
- W2603252472 hasRelatedWork W3016515934 @default.
- W2603252472 hasRelatedWork W3142102997 @default.
- W2603252472 isParatext "false" @default.
- W2603252472 isRetracted "false" @default.
- W2603252472 magId "2603252472" @default.
- W2603252472 workType "article" @default.